US2017189359A1PendingUtilityA1

Graphene Nanostructure-Based Pharmaceutical Composition for Preventing or Treating Neurodegenerative Diseases

40
Assignee: UNIV SEOUL NAT R & DB FOUNDPriority: Apr 4, 2014Filed: Apr 3, 2015Published: Jul 6, 2017
Est. expiryApr 4, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Byung Hee HongJe-Min YooHanseok KoDonghoon Kim
A61P 3/10A61P 9/10A61P 3/00A61P 25/28A61P 25/16A61P 25/14A61P 21/02A61P 25/00A61P 21/00A61K 31/194A61K 49/0021A61K 41/0052A61K 47/50A61N 5/062A61N 2005/066C01B 32/182A61K 47/06A61K 49/0052A61K 33/44A61K 47/02A61N 2005/067A61N 5/067C01B 2204/32
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the pharmaceutical composition including a graphene nanostructure as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for preventing or treating neurodegenerative diseases, comprising a graphene nanostructure as an active ingredient. 
     
     
         2 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 , further comprising a pharmaceutically acceptable carrier or excipient. 
     
     
         3 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the neurodegenerative diseases include a member selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's chorea, HIV dementia, stroke, senile systemic amyloidosis, primary systemic amyloidosis, secondary systemic amyloidosis, type II diabetes, amyotrophic amyloidosis, hemodialysis-related amyloidosis, transmissible spongiform encephalopathy, and multiple sclerosis.   
     
     
         4 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 2 ,
 wherein the pharmaceutically acceptable carrier or excipient includes a member selected from the group consisting of vaseline, lanolin, polyethylene glycol, alcohol, and combinations thereof.   
     
     
         5 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the graphene nanostructure includes graphite, graphene, or graphene quantum dots.   
     
     
         6 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the graphene nanostructure inhibits fibril formation caused by protein misfolding.   
     
     
         7 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the graphene nanostructure inhibits transition of misfolded proteins.   
     
     
         8 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the graphene nanostructure is not accumulated in the body.   
     
     
         9 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein a terminal functional group of the graphene nanostructure is bonded to a material targeting a neuronal protein.   
     
     
         10 . The pharmaceutical composition for preventing or treating neurodegenerative diseases of  claim 1 ,
 wherein the graphene nanostructure shows a photothermal effect upon irradiation of a far-infrared laser.

Join the waitlist — get patent alerts

Track US2017189359A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.